OncologyNews archives 2018

The ESMO OncologyPRO news, provided in partnership with medwireNews.

Date Title Topic
24 Dec 2018 Chemotherapy For Most Solid Tumours Linked To Increased Haematopoietic Malignancy Risk Aetiology, Epidemiology, Screening and Prevention - Complications/Toxicities of Treatment
21 Dec 2018 Pembrolizumab Shows ‘Modest Activity’ Against Heavily Pretreated Oesophageal Cancer Oesophageal Cancer - Immunotherapy
20 Dec 2018 Malignant Solitary Fibrous Tumours Show Pazopanib Response Soft Tissue Sarcomas - Anticancer Agents
19 Dec 2018 Clinical Outcomes Of EGFR-Mutant SCLC Described Thoracic Malignancies - Small Cell Lung Cancer - Personalised/Precision Medicine - Anticancer Agents
18 Dec 2018 SURTIME Indicates Role For Sunitinib Before Cytoreductive Nephrectomy In mRCC Patients Renal Cell Cancer - Anticancer Agents - Surgical Oncology
17 Dec 2018 Ixazomib ‘Additional Option’ For Multiple Myeloma Post-Transplant Maintenance Plasma Cell Dyscrasias - Anticancer Agents
14 Dec 2018 Long-Term Survival Benefit Of Radical Prostatectomy For Localised Prostate Cancer Characterised Prostate Cancer - Surgical Oncology
13 Dec 2018 Patient-Reported Outcomes Of IMPORT LOW Trial Revealed Breast Cancer - Complications/Toxicities of Treatment - Radiation Oncology
12 Dec 2018 Caution Warranted Regarding Alternative Controls To Assess HER2 Amplification Status Breast Cancer - Pathology/Molecular Biology
11 Dec 2018 Rare Haematological irAEs Reported For PD-1, PD-L1 Inhibitor Use Immunotherapy - Complications/Toxicities of Treatment
10 Dec 2018 Recurrent Glioblastoma OS Better With Regorafenib Than Lomustine Central Nervous System Malignancies - Anticancer Agents
07 Dec 2018 Direct Oral Anticoagulants Show Promise For Preventing VTE In Cancer Patients Supportive Measures
06 Dec 2018 Genetic Mechanism Of Venetoclax Resistance In CLL Patients Identified Haematological Malignancies - Leukaemia - Translational Research - Anticancer Agents
06 Dec 2018 Shorter Chemotherapy Course Feasible For Younger DLBCL Patients Haematological Malignancies - Lymphomas - Anticancer Agents
05 Dec 2018 2-Year ZUMA-1 Results Add Support For Axicabtagene Ciloleucel In Refractory Large B-Cell Lymphoma Haematological Malignancies - Lymphomas - Immunotherapy